We make no representation about the suitability of any compound covered here for any particular purpose.
For millions of Americans relying on GLP-1 receptor agonists like tirzepatide and semaglutide for weight management and type 2 diabetes, the compounding pharmacy has become a critical, and sometimes confusing, source of medication. In 2026, the U.S. Food and Drug Administration (FDA) has issued updated guidance that significantly tightens quality standards for compounded versions of these drugs. This article breaks down what the new guidance says, why it matters for patient safety, and how it changes the landscape for pharmacies, telehealth providers, and consumers.
Why the FDA Is Focusing on Compounded GLP-1 Agonists
Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy, Rybelsus) have been in persistent shortage since their approvals, driving unprecedented demand for compounded alternatives. Compounded drugs are made by state-licensed pharmacies or outsourcing facilities when a patient has a specific medical need that FDA-approved products cannot meet, often due to shortages, allergies, or dosage requirements. However, the FDA has long warned that compounded peptides carry higher risks than FDA-approved drugs because they do not undergo the same premarket review for safety, effectiveness, and quality.
In 2025, the FDA conducted a series of inspections and sample analyses of compounded tirzepatide and semaglutide products. The agency found alarming inconsistencies: some samples contained impurities, incorrect active ingredient concentrations, or unapproved salt forms. These findings prompted the updated guidance, which aims to establish a uniform quality floor for all pharmacies compounding GLP-1 agonists. The guidance also aligns with the FDA's broader crackdown on unsafe compounding practices, as detailed in our earlier coverage of how FDA's tirzepatide quality failures could trigger semaglutide inspections.
Key Changes in the 2026 Guidance
The updated guidance, titled "Compounding of Tirzepatide and Semaglutide Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act," introduces several new requirements and clarifications. Here are the most significant changes:
- Mandatory use of FDA-approved active pharmaceutical ingredients (APIs): Compounding pharmacies must source tirzepatide and semaglutide APIs only from FDA-registered facilities that meet current good manufacturing practice (CGMP) standards. This eliminates the use of research-grade or non-pharmaceutical-grade peptides, which were a common source of contamination.
- Prohibition of salt forms not found in approved drugs: The FDA explicitly states that compounding pharmacies may not use semaglutide sodium or semaglutide acetate, salt forms that differ from the base semaglutide used in approved products. These salt forms have different pharmacokinetic profiles and have not been shown to be safe or effective.
- Enhanced stability and sterility testing: Pharmacies must conduct and document stability testing for compounded GLP-1 products to establish beyond-use dates. Sterility testing is required for all injectable compounds, with specific protocols for multi-dose vials.
- Limits on bulk compounding: The guidance clarifies that pharmacies cannot compound large quantities of tirzepatide or semaglutide in anticipation of prescriptions. Compounding must be patient-specific (for 503A pharmacies) or based on a valid prescription for an identified patient (for 503B outsourcing facilities).
- Labeling and patient education requirements: Compounded products must include clear labeling that the product is not FDA-approved, along with storage instructions, beyond-use date, and a statement of the pharmacy's contact information for adverse event reporting.
These changes are designed to bring compounded GLP-1 agonists closer to the quality standards of FDA-approved drugs, but they also raise the bar for pharmacies that may lack the resources to comply.
Impact on 503A Pharmacies vs. 503B Outsourcing Facilities
The guidance distinguishes between traditional compounding pharmacies (Section 503A) and outsourcing facilities (Section 503B). Both are subject to the new quality standards, but the operational impact differs.
503A pharmacies are typically smaller, state-licensed operations that compound medications for individual patients based on a prescription. Under the new guidance, these pharmacies must now source APIs from FDA-registered suppliers, which may be more expensive and harder to obtain. They must also invest in sterility testing equipment or contract with third-party labs. Many small pharmacies may decide to stop compounding GLP-1 agonists altogether due to the cost and complexity.
503B outsourcing facilities are larger, FDA-registered entities that can compound larger batches without patient-specific prescriptions, but they must follow CGMP requirements. The new guidance reinforces their obligation to use only FDA-approved APIs and to conduct extensive quality testing. While 503B facilities are better positioned to comply, they may face supply chain challenges as demand for pharmaceutical-grade tirzepatide and semaglutide APIs surges.
For patients, this could mean fewer compounding options, longer wait times, and potentially higher prices, but also greater assurance of product quality. The shift is already visible in the telehealth market, where some providers are adjusting their sourcing strategies, as discussed in our analysis of Ozari Health's pricing and FDA enforcement risk.
What the Guidance Means for Telehealth and Online Prescribers
Telehealth platforms have been a major channel for compounded GLP-1 prescriptions, often partnering with specific pharmacies to fulfill orders. The new FDA guidance places additional responsibility on prescribers to ensure that the compounding pharmacy they use is compliant. Specifically, prescribers should verify that the pharmacy is licensed in the patient's state, sources APIs appropriately, and follows the new quality standards.
The guidance also warns against prescribing compounded GLP-1 agonists for cosmetic weight loss when an FDA-approved product is available and not in shortage. While tirzepatide and semaglutide remain on the FDA's drug shortage list as of early 2026, the agency has signaled that shortages may resolve soon. Once a drug is removed from the shortage list, compounding of that drug under 503A becomes largely prohibited, and 503B facilities face tighter restrictions. This creates uncertainty for telehealth companies that have built their business models on compounded peptides.
Some telehealth providers are proactively shifting to FDA-approved products or partnering with 503B outsourcing facilities that can demonstrate compliance. Others are exploring alternative peptides, though the FDA's recent panel vote on six peptides could further restrict those options, a development we covered in our report on the FDA panel vote.
Patient Safety and Quality Concerns
The core driver of the FDA's updated guidance is patient safety. Compounded GLP-1 agonists have been linked to adverse events, including dosing errors, infections, and allergic reactions. In 2025, the FDA received over 300 adverse event reports related to compounded semaglutide and tirzepatide, including several hospitalizations. Many of these events were traced to products that contained the wrong concentration of active ingredient or were contaminated during compounding.
The new quality standards aim to reduce these risks by ensuring that every compounded GLP-1 product meets minimum purity, potency, and sterility thresholds. For patients, this means:
- Lower risk of contamination: Mandatory sterility testing and CGMP-compliant APIs reduce the chance of bacterial or fungal contamination.
- More accurate dosing: Prohibition of unapproved salt forms and mandatory potency testing help ensure that each dose contains the labeled amount of active drug.
- Clearer labeling: Enhanced labeling requirements help patients understand storage conditions, beyond-use dates, and how to report side effects.
However, patients should remain vigilant. Even with the new guidance, compounded drugs are not FDA-approved, and their safety and effectiveness have not been established through the same rigorous clinical trials as brand-name products. Patients should always consult their healthcare provider before starting or switching to a compounded medication.
Enforcement and Compliance Timeline
The FDA's updated guidance is technically non-binding, but it represents the agency's current thinking and is used as a basis for enforcement actions. The FDA has stated that it will prioritize inspections of pharmacies that compound GLP-1 agonists and will take action against those that do not meet the new standards. Enforcement tools include warning letters, injunctions, seizures, and criminal prosecution in egregious cases.
The guidance became effective immediately upon publication in January 2026, but the FDA has indicated a phased enforcement approach. During the first six months, the agency will focus on education and outreach, helping pharmacies understand the new requirements. After that, routine inspections will include checks for API sourcing, salt form compliance, and sterility testing documentation. Pharmacies that fail to comply may face regulatory action.
For consumers, this means that the quality of compounded GLP-1 products should improve over the course of 2026, but there may be a transition period during which some non-compliant products remain on the market. Patients should ask their pharmacy about compliance with the new FDA guidance and request documentation of API sourcing and sterility testing if they have concerns.
What Patients Should Do Now
If you are currently using a compounded tirzepatide or semaglutide product, or considering starting one, here are practical steps to protect yourself:
- Verify your pharmacy's credentials: Ask whether the pharmacy is a 503A or 503B facility, and confirm it is licensed in your state. You can check the FDA's website for a list of registered outsourcing facilities.
- Ask about API sourcing: Inquire where the pharmacy obtains its tirzepatide or semaglutide API. It should be from an FDA-registered manufacturer that follows CGMP. Avoid pharmacies that use research-grade or "for laboratory use only" peptides.
- Check the label: The product label should clearly state that it is compounded, not FDA-approved, and include a beyond-use date, storage instructions, and the pharmacy's contact information.
- Report any adverse effects: If you experience unusual side effects, report them to your healthcare provider and to the FDA's MedWatch program. This helps the agency identify problem pharmacies and products.
- Stay informed about shortages: The FDA maintains a drug shortage database. If tirzepatide or semaglutide is removed from the shortage list, compounding of that drug may become illegal. Discuss alternatives with your doctor.
For a deeper look at how the FDA's evolving stance could affect access, see our article on how the new draft guidance could reshape compounded GLP-1 access.
The Future of Compounded GLP-1 Agonists
The 2026 guidance is part of a broader regulatory shift toward tighter oversight of compounded peptides. The FDA has signaled that it will continue to monitor the quality of compounded GLP-1 products and may issue additional guidance or regulations as new data emerge. The agency is also working with state pharmacy boards to harmonize standards and improve information sharing.
For the compounding industry, the new guidance will likely accelerate consolidation. Smaller pharmacies that cannot afford the required testing and API sourcing may exit the GLP-1 market, while larger 503B facilities and well-capitalized 503A pharmacies will expand. This could lead to more consistent product quality but also reduced patient choice and potentially higher costs.
For patients, the key takeaway is that compounded GLP-1 agonists are becoming safer and more standardized, but they are still not equivalent to FDA-approved drugs. The decision to use a compounded product should be made in consultation with a healthcare provider who understands the risks and benefits. As the regulatory landscape continues to evolve, staying informed is the best defense against unsafe products.
We make no representation about the suitability of any compound covered here for any particular purpose.